Clinical trial
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After…
NCT00051103 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00051103 |
|---|---|
| Title | Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. |
| Official title | An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer, Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Investigational Cancer Drug |
| Start date | Oct 1, 2002 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jan 6, 2003 |
| Last update posted | Apr 15, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: